Octreotide in the Treatment of Lymphorrhea After Axillary Node Dissection: A Prospective Randomized Controlled Trial

Carcoforo, Paolo; Soliani, Giorgio; Maestroni, Umberto; Donini, Annibale; Inderbitzin, Daniel; Hui, Thomas; Lefor, Alan Kawarai; Avital, Itzhak; Navarra, Giuseppe

doi:10.1016/s1072-7515(02)01757-x

Cited by 59 publications

(46 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only one study has demonstrated the effectiveness of octreotide administration in the post-operative period after ALND, on amount and duration of lymphorrhea, but more randomized trials are needed to confirm the real advantage of its use [31]. In any case, octreotide administration did not influence the hospital stay, or the duration of drain.…”

Section: Discussionmentioning

confidence: 88%

Does LigaSure(TM) reduce fluid drainage in axillary dissection? A randomised prospective clinical trial

Antonio¹

2015

ecancer

View full text Add to dashboard Cite

Background: Axillary lymph node dissection (ALND) is an integral part of breast cancer treatment. It is required in about 40-50% of patients. The placement of a drain in the axilla after an operation is current surgical practice. Short surgical stay programmes increase operating efficiency and reduce medical care costs, without compromising quality of care. LigaSure TM is a new haemostatic device that uses bipolar energy to seal vessels. The aim of this study is to determine whether axillary dissection with LigaSure TM reduces the time of wound drainage, the duration of surgical intervention and the volume of drainage after treatment.

show abstract

Section: Discussionmentioning

confidence: 88%

Does LigaSure(TM) reduce fluid drainage in axillary dissection? A randomised prospective clinical trial

Antonio¹

2015

ecancer

View full text Add to dashboard Cite

show abstract

“…It has been shown in animal models to reduce local inflammatory reaction, which is one of the pathophysiological mechanisms implicated in seroma formation and probably can have a direct effect on the lymphatic circulation by reduction of lymph production. Carcoforo et al [49] in a prospective trial randomized 261 consecutive patients following axillary dissection for breast cancer into treatment group who received 0.1mg octreotide subcutaneously thrice a day for 5 days starting on the first postoperative day and the control group who received no treatment. In the control group, the mean volume of seroma was 94.6+ 19 mL/day and the average duration was 16.7+3.0 days, where as in the treatment group, the mean volume of seroma was 65.4+21.1 ml/day (p<0.0001) and the average duration was 7.1+2.9 days (p<0.0001).…”

Section: The Role Of Octreotidementioning

confidence: 99%

Seroma Formation after Mastectomy: Pathogenesis and Prevention

Sampathraju

Rodrigues

2010

Indian J Surg Oncol

View full text Add to dashboard Cite

Post mastectomy seroma remains an unresolved quandary as the risk factors for its formation have still not been identified. Seromas of the axillary space following breast surgery can lead to significant morbidity and delay in the initiation of adjuvant therapy. Various techniques and their modifications have been practiced and published in English literature, but there seems to be no consensus. In this article, all aspects of seroma formation from pathogenesis to prevention including drug therapies have been discussed.

show abstract

“…One adult series of patients with advanced malignancy found successful treatment of chylous effusions with subcutaneous octreotide and a fat-free diet. Chylous effusions associated with lymphoma have also been successfully treated with octreotide [55], and octreotide has been used for treatment of postaxillary dissection lymphorrhea [56].…”

Section: Chylous Effusionsmentioning

confidence: 99%

Established and potential therapeutic applications of octreotide in palliative care

Prommer

2008

Support Care Cancer

View full text Add to dashboard Cite

Octreotide acetate was developed as a pharmacologically stable, long-acting analogue of the hormone somatostatin. Mimicking the actions of somatostatin, octreotide has been used for its antisecretory effects. Randomized control trials have established the efficacy of octreotide for malignant bowel obstruction and for chemotherapy-induced diarrhea. Octreotide has proven to be an effective agent for symptoms of carcinoid syndrome. Newer uses include for bone marrow transplantation, infectious diarrheal syndromes, and management of hepatic metastases. More evidence is needed for the establishment of its efficacy for hypercalcemia, pain, pleural effusions, diarrhea after celiac plexus block, and malignant ascites.

show abstract

Octreotide in the Treatment of Lymphorrhea After Axillary Node Dissection: A Prospective Randomized Controlled Trial

Cited by 59 publications

References 17 publications

Does LigaSure(TM) reduce fluid drainage in axillary dissection? A randomised prospective clinical trial

Does LigaSure(TM) reduce fluid drainage in axillary dissection? A randomised prospective clinical trial

Seroma Formation after Mastectomy: Pathogenesis and Prevention

Established and potential therapeutic applications of octreotide in palliative care

Contact Info

Product

Resources

About